A patient with severe atopic dermatitis was treated with mycophenolate mofetil (MMF) and developed lung problems (interstitial lung disease) as a side effect. After stopping MMF and receiving steroid treatment, the patient's lung condition improved.
-
Reversible interstitial lung disease following treatment of atopic dermatitis with mycophenolate mofetil
Reversible interstitial lung disease following treatment of atopic dermatitis with mycophenolate mofetil
T J Tull, T Toma, H P Menagé
DOI: 10.1111/ced.12843
Case Reports
•
1 participants
•
2016
•
0 citations
Key insights related to Cellcept from this study:
-
What is this paper about?
-
How did the authors study this?
Study conclusions come from a case report. Conclusions may not represent the general population due to the limited sample sizes involved.
-
What populations did the authors study?
{'age': '37 years', 'ad_severity': 'severe', 'prior_treatments': ['phototherapy', 'ciclosporin', 'azathioprine'], 'total_patients': 1, 'baseline_characteristics': {'gender': 'female'}, 'interventions': 'Mycophenolate mofetil (500mg daily, increased to 1g twice daily)', 'comparators': 'none'}
-
What did the authors find?
Analyzing metric: Other (clinical response).
Findings show: Invervention leads to good clinical effect initially, followed by adverse event.
Resulting in: MMF showed good clinical effect but had to be discontinued due to serious side effects. -
What conclusions can we draw?
nan
Did this article interest you?
As a member of the Lemma Health community, you'll stay up to date with research, hear about new products, and get exclusive access to discounts.
Ready for better skin health?
At Lemma Health, we provide evidence-based skin care. Access dermatologists in all 50 states. Appointments available within 3 days. Receive your medications delivered. Get ongoing 24/7/365 support. Coordinate your care across specialties.